GlobeNewswire by notified

mPrest Announces Expansion of Transformer Health Management Partnership with Energisa Group

Share

Following a successful year-long first phase, Energisa Group will continue to leverage mPrest’s mTHM platform to ensure the reliability and security of their energy supply across an expanded amount of system transformers

CATAGUASES, Brazil and TEL AVIV, Israel, Jan. 19, 2022 (GLOBE NEWSWIRE) -- mPrest, a leading developer and provider of distributed asset orchestration and optimization software for the energy market, today announced the expansion of an ongoing partnership to provide further use of mPrest’s Transformer Health Management (mTHM) system to Energisa Group, a leading energy distribution group in Brazil. mTHM is part of mPrest’s Asset Performance Management system (APM), a holistic solution that supports a rich set of energy assets.

This is the second phase of a deal between mPrest and Energisa to monitor and manage the health and reliability of Energisa’s power transformers and grid. Following the successful first phase of the partnership, which began one year ago and included 112 transformers managed by mPrest’s mTHM solution, the expanded contract will include an additional 88 Energisa transformers. A total of 200 transformers will now utilize mTHM’s real-time monitoring, powerful analytics, highly accurate predictions and condition alerts.

As one of the largest energy distribution and transmission utilities in Brazil, Energisa has nine distributed system operators (DSOs) across Brazil’s five regions. These DSOs will continue to leverage mTHM’s predictive capabilities to reduce transformer malfunctions and critical failures as they provide power to approximately 8 million customers.

“We’re proud to continue our partnership with Energisa Group as we shape the future of the power grid together,” said Andrew Bennett, CEO of mPrest Inc. “Our mTHM is a proven solution that has demonstrated an improved method of detecting transformer issues before critical failures occur. We look forward to expanding our work with Energisa and tapping into their expertise to enhance and improve the capabilities of our product. We’re focused on improving transformer health and predicting the future through mTHM for Energisa, as they deliver reliable power to their many customers.”

mTHM will allow Energisa to continue to monitor critical transmission and distribution transformers to verify transformer health, analyze the risk of failure, and identify areas of degradation or concern that can be mitigated through maintenance or repair. This provides sizable cost and time savings in the short-term, as failures have the potential to impact thousands of customers. Long-term life cycle cost savings on operations are also being realized through the mTHM platform as transformer lifetimes are extended.

AboutmPrest – Empower Digital Transformation. Now.
Leveraging its unparalleled experience and expertise in real-time mission-critical command and control software, mPrest has developed the world-leading distributed asset orchestration and optimization software. mPrest’s micro-services based, real-time orchestration and optimization platform brings the power of AI and IoT to the digital transformation of various industries, from energy and smart cities, through oil & gas, connected cars, water, defense and other industry 4.0 applications. mPrest’s applications suite, including Distributed Energy Resources Management Systems (DERMS) and Asset Performance Management (APM) are deployed on premise or in the cloud in record time in the most forward-looking and efficient organizations worldwide, including some of the world’s largest energy companies. mPrest’s vendor-agnostic product suite interfaces with millions of sensors, devices, machines, assets, subsystems, IT and OT applications, creating a system of systems that provides end-to-end visibility and control over complex and distributed operations. Visit us at www.mprest.com

Media inquiries
FischTank PR
mprest@fischtankpr.com

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Global COVID-19 Memorial Will Honor Pandemic Frontline & Essential Workers24.4.2024 16:18:34 CEST | Press release

CHICAGO, April 24, 2024 (GLOBE NEWSWIRE) -- A monument park and website honoring medical frontline and essential workers worldwide who risked their lives during the COVID-19 pandemic will break ground this summer in Chicago, Illinois. The COVID-19 Monument of Honor, Remembrance, and Resilience draws attention to the enormous sacrifices made by these workers and the stress they encountered. Further, the COVID-19Monument pays tribute to those who lost the battle to COVID-19, now more than seven million individuals. Accessible 24/7, the monument park and website will serve as a gathering space of healing, reflection, & wellness. The website will invite participation from all, and preserve the oral history of essential workers, pandemic survivors (especially those suffering from Long-COVID) and serve as a permanent memorial to lost loved ones. Sally Metzler, Ph.D., the Chair of the Commission, emphasized the epic nature of the impact of the pandemic, “No other event in recent history has t

Fly Play hf.: Increase of share capital24.4.2024 16:16:35 CEST | Press release

Reference is made to the announcement of Fly Play hf. (“PLAY” or the “Company”) on April 11, 2024, regarding the results of a funding round. In a meeting held today, the Company’s Board of Directors decided to exercise the authority granted by the AGM to increase the Company’s share capital by issuing new shares by up to 1,200,000,000 shares in nominal value. As previously announced, the total amount of the authorization will not be used. The Company's Board of Directors decided at a meeting today to increase the Company's share capital by issuing 1,023,155,559 new shares, each with a nominal value of 1 ISK. The new shares will be delivered to investors on April 29, 2024, and admission to trading of the new shares on Nasdaq First North Growth Market Iceland is scheduled to commence on the same day under the symbol PLAY (ISIN: IS0000032936). Following the share capital increase, PLAY has 1,891,598,895 shares outstanding.

Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting24.4.2024 16:14:55 CEST | Press release

NON-REGULATORY PRESS RELEASE Oslo, April 24, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces that the data from the Phase II clinical trial INITIUM (NCT04382664), will be presented in a poster session at the 2024 ASCO Annual Meeting, taking place May 31 – June 4, 2024, in Chicago, IL & Online. INITIUM is an Ultimovacs-sponsored randomized, comparative, multicenter Phase II trial evaluating the company’s therapeutic cancer vaccine candidate UV1 in combination with the checkpoint inhibitors ipilimumab and nivolumab as first-line treatment in unresectable or metastatic malignant melanoma. The trial was conducted at 39 hospitals across the U.S., U.K., Belgium, and Norway, and 156 patients were enrolled between June 2020 and July 2022. The poster presentation features key findings and analyses after a minimum 18-month follow-up of the patients in the trial. Presentation Details: Abstract Num

Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting24.4.2024 16:00:00 CEST | Press release

Petosemtamab in combination with pembrolizumab in 1L HNSCC initial interim clinical data selected for rapid oral session presentation MCLA-145 as monotherapy or in combination with pembrolizumab in solid tumors initial interim clinical data selected for rapid oral session presentation MCLA-129 in NSCLC with c-MET exon 14 skipping mutations initial interim clinical data selected for poster presentation UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the acceptance of three abstracts for presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, Illinois on May 31- June 4, 2024. Rapid oral presentation: Title: Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of recurrent/metastatic (r/m

Correction to stock exchange release: Siili Solutions Plc: Business review, 1 January – 31 March 202424.4.2024 15:55:00 CEST | Press release

Correction to stock exchange release: Siili Solutions Plc: Business review, 1 January – 31 March 2024 Siili Solutions Plc Stock exchange release 24 April 2024 at 16:55 This is a correction to the stock exchange release published by Siili Solutions Plc on 24 April 2024 at 9:45 am by which the company published its business review for the period 1 January – 31 March 2024. In section “Key events for January-March” it was stated that “75% of Siili employees have completed a GenAI certificate”. The correct information is that “51% of Siili employees in Finland have completed a GenAI certificate”. In addition, in the CEO review it was stated that “By the end of March, 75% of Siili’s employees in Finland had achieved the first-level certification.” The completion percentage was incorrect and the correct information is that “By the end of March, 51% of Siili’s employees in Finland had achieved the first-level certification.” The corrected release is stated below as a whole and the revised repo

HiddenA line styled icon from Orion Icon Library.Eye